SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced its participation at two upcoming healthcare investor conferences
in September.
- Citi 12th Annual Biotech Conference. Calithera will host meetings with investors at the
conference in Boston on Wednesday September 6, 2017.
-
Wells Fargo Securities Healthcare Conference. Susan M. Molineaux, Ph.D, the company’s Founder, President
and Chief Executive Officer, will present in Boston on Thursday, September 7, at 2:50 p.m. Eastern Time. The presentation will
be webcast live, and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small
molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead
product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes
advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being
evaluated in Phase 2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology
metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by
myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and
survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is being developed in collaboration
with Incyte Corporation and is currently in a Phase 1 clinical trial. Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events,
conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to
the timing of Calithera’s clinical trials, the clinical and commercial potential of its product candidates, Calithera’s ability to
fund its clinical programs, and Calithera’s receipt of clinical data from its clinical trials. Because such statements are subject
to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking
statements. The potential product candidates that Calithera develops may not progress through clinical development or receive
required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety,
potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial
to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may
have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak
only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking
statements to reflect future events or circumstances.
Contact: Jennifer McNealey ir@Calithera.com 650-870-1071
